TheraRadar
← Back
Data updated: Jul 17, 2026

Dynavax Technologies Corporation

Biotech
Infectious DiseaseOncology Execution: Excellent

Dynavax Technologies Corporation is a biotechnology company focused on Infectious Disease, Oncology. Key products include Heplisav-B.

2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

Dynavax Technologies Corporation at a Glance

  • Strong track record with 83% execution quality across 16 trials
  • Fast trial execution (20 months median completion)

Dynavax Technologies Corporation's Key Drugs

Dynavax Technologies Corporation's core commercial portfolio centers on Heplisav-B, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.

Heplisav-B
Approved 2017

Dynavax Technologies Corporation's Recent FDA Approvals

New NDA/BLA approvals for Dynavax Technologies Corporation over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

Dynavax Technologies Corporation's Therapeutic Areas

Dynavax Technologies Corporation's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 70%
0 drugs Phase 2: 1 Phase 1: 5
Oncology 30%
0 drugs Phase 1: 3

Dynavax Technologies Corporation's Top Competitors

Dynavax Technologies Corporation's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Infectious Disease
Merck big-pharma
Oncology, Infectious Disease
Baxter specialty
Infectious Disease, Oncology
AbbVie big-pharma
Oncology, Infectious Disease
Johnson & Johnson big-pharma
Oncology, Infectious Disease

Dynavax Technologies Corporation Pipeline Snapshot

Dynavax Technologies Corporation has 9 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 8 Phase 1.

0
Phase 3
1
Phase 2
8
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Heplisav-B leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/4 completed
  • • Speed: 20 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges